Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

27 Nov 2007

Abstract excerpt

Elevated expression of members of the BCL-2 pro-survival family of proteins can confer resistance to apoptosis in cancer cells. Small molecule obatoclax (GX15-070), which is predicted to occupy a hydrophobic pocket within the BH3 binding groove of BCL-2, antagonizes these members and induces apoptosis, dependent on BAX and BAK. Reconstitution in yeast confirmed that obatoclax acts on the pathway and overcomes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Cell death mechanisms and regulation
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18040043
DOI: 10.1073/pnas.0709443104

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosisPMID 18040043Read ↗

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myelomaSemantic proximity Read ↗

Anti-cancer drug discovery and developmentSemantic proximity Read ↗

Drugs targeting Bcl-2 family members as an emerging strategy in cancerSemantic proximity Read ↗

BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosisSemantic proximity Read ↗

Mcl-1 inhibitors: a patent reviewSemantic proximity Read ↗

Designed BH3 Peptides with High Affinity and Specificity for Targeting Mcl-1 in CellsSemantic proximity Read ↗

The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cellsSemantic proximity Read ↗

Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.Semantic proximity Read ↗

Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.Semantic proximity Read ↗

The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cellsSemantic proximity Read ↗

Differential regulation of BAX and BAK apoptotic activity revealed by a novel small moleculeSemantic proximity Read ↗

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the ClinicSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.